title: Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure.
abstract: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones that are involved in water and electrolyte homeostasis in heart failure. Although both hormones exert almost identical biological actions, the differential regulation of cardiac ANP and BNP mRNA in compensated and overt heart failure is not known. To study the hypothesis that cardiac BNP is more specifically induced in overt heart failure, a large aortocaval shunt of 30 days duration was produced in rats and compared with compensated heart failure. Compensated heart failure was induced either by a small shunt of 30 days duration or by a large shunt of 3 days duration. Both heart failure models were characterized by increased cardiac weight, which was significantly higher in the large-shunt model, and central venous pressure. Left ventricular end-diastolic pressure was elevated only in the overt heart failure group (control: 5.7 +/- 0. 7; small shunt: 8.6 +/- 0.9; large shunt 3 days: 8.5 +/- 1.7; large shunt 30 days: 15.9 +/- 2.6 mmHg; P < 0.01). ANP and BNP plasma concentrations were elevated in both heart failure models. In compensated heart failure, ANP mRNA expression was induced in both ventricles. In contrast, ventricular BNP mRNA expression was not upregulated in any of the compensated heart failure models, whereas it increased in overt heart failure (left ventricle: 359 +/- 104% of control, P < 0.001; right ventricle: 237 +/- 33%, P < 0.01). A similar pattern of mRNA regulation was observed in the atria. These data indicate that, in contrast to ANP, cardiac BNP mRNA expression might be induced specifically in overt heart failure, pointing toward the possible role of BNP as a marker of the transition from compensated to overt heart failure.
authors.affiliation: Franz-Volhard-Clinic, Max-Delbrück-Center for Molecular Medicine, University Hospital Charité, Humboldt-University of Berlin, 13125 Berlin, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Langenickel
authors.forename: I
authors.initials: I
authors.lastname: Pagel
authors.forename: K
authors.initials: K
authors.lastname: Höhnel
authors.forename: R
authors.initials: R
authors.lastname: Dietz
authors.forename: R
authors.initials: R
authors.lastname: Willenbrock
mesh_terms: D000818:Animals; D001166:Arteriovenous Shunt, Surgical; D009320:Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism*; D002496:Central Venous Pressure / Q000502:physiology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics / Q000378:metabolism; D006325:Heart Atria / Q000378:metabolism / Q000473:pathology; D006333:Heart Failure / Q000378:metabolism*; D006352:Heart Ventricles / Q000378:metabolism / Q000473:pathology; D006439:Hemodynamics; D008168:Lung / Q000502:physiology; D008297:Male; D009200:Myocardial Contraction / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000235:genetics / Q000378:metabolism*; D009929:Organ Size; D012333:RNA, Messenger / Q000096:biosynthesis*; D051381:Rats; D017208:Rats, Wistar; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D012333:RNA, Messenger; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases